{
    "nct_id": "NCT04576455",
    "official_title": "A Phase II, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of GDC-9545 Compared With Physician's Choice of Endocrine Monotherapy in Patients With Previously Treated Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer",
    "inclusion_criteria": "* Women who are postmenopausal or premenopausal/perimenopausal\n* For women who are premenopausal or perimenopausal and for men: willing to undergo and maintain treatment with approved LHRH agonist therapy for the duration of study treatment\n* Locally advanced or metastatic adenocarcinoma of the breast, not amenable to treatment with curative intent\n* Documented ER-positive tumor and HER2-negative tumor, assessed locally\n* Disease progression after treatment with one or two lines of systemic therapy (but not more than one prior targeted therapy) in the locally advanced or metastatic setting\n* Measurable disease as defined per RECIST v.1.1 or bone only disease which must have at least one predominantly lytic bone lesion confirmed by CT or MRI which can be followed\n* Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1\n* Adequate organ function\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Prior treatment with a selective estrogen receptor degrader (SERD), with the exception of fulvestrant, if fulvestrant treatment was terminated at least 28 days prior to randomization\n* Treatment with any investigational therapy within 28 days prior to randomization\n* Advanced, symptomatic, visceral spread that is at risk of life-threatening complications\n* Known active uncontrolled or symptomatic CNS metastases, carcinomatous meningitis, or leptomeningeal disease\n* Active cardiac disease or history of cardiac dysfunction\n* Pregnant or breastfeeding",
    "miscellaneous_criteria": ""
}